Bank of New York Mellon Corp boosted its stake in shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) by 20.9% during the second quarter, Holdings Channel reports. The institutional investor owned 99,629 shares of the company’s stock after buying an additional 17,195 shares during the period. Bank of New York Mellon Corp owned approximately 0.35% of Atara Biotherapeutics worth $2,243,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in ATRA. JPMorgan Chase & Co. raised its position in Atara Biotherapeutics by 3.1% in the first quarter. JPMorgan Chase & Co. now owns 62,600 shares of the company’s stock valued at $1,191,000 after buying an additional 1,900 shares in the last quarter. A.R.T. Advisors LLC raised its position in Atara Biotherapeutics by 79.6% in the first quarter. A.R.T. Advisors LLC now owns 63,941 shares of the company’s stock valued at $1,216,000 after buying an additional 28,330 shares in the last quarter. RTW Investments LLC raised its position in Atara Biotherapeutics by 11.1% in the first quarter. RTW Investments LLC now owns 473,126 shares of the company’s stock valued at $9,004,000 after buying an additional 47,274 shares in the last quarter. Finally, Bridger Management LLC purchased a new position in Atara Biotherapeutics during the first quarter valued at $14,072,000. 75.50% of the stock is currently owned by institutional investors and hedge funds.
Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded down 0.47% during midday trading on Wednesday, reaching $18.99. The company’s stock had a trading volume of 334,998 shares. The firm’s market capitalization is $547.12 million. The stock has a 50 day moving average of $20.67 and a 200 day moving average of $20.30. Atara Biotherapeutics Inc. has a 52 week low of $13.31 and a 52 week high of $40.80.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Monday, August 8th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.05. On average, equities research analysts predict that Atara Biotherapeutics Inc. will post ($2.85) earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on the company. JMP Securities reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research note on Saturday, July 9th. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 2nd. Canaccord Genuity reiterated a “buy” rating on shares of Atara Biotherapeutics in a report on Tuesday, June 7th. Jefferies Group reiterated a “buy” rating and set a $25.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, August 9th. Finally, Goldman Sachs Group Inc. downgraded Atara Biotherapeutics from a “neutral” rating to a “sell” rating and dropped their target price for the company from $23.00 to $16.00 in a report on Thursday, September 15th. Three equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Atara Biotherapeutics presently has an average rating of “Hold” and an average price target of $26.14.
In other news, insider Christopher Haqq sold 1,346 shares of the company’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $22.32, for a total transaction of $30,042.72. Following the completion of the sale, the insider now owns 295,294 shares in the company, valued at approximately $6,590,962.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Isaac E. Ciechanover sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $22.11, for a total value of $212,256.00. Following the sale, the chief executive officer now owns 223,228 shares of the company’s stock, valued at approximately $4,935,571.08. The disclosure for this sale can be found here. Insiders own 16.10% of the company’s stock.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc. (NASDAQ:ATRA).
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.